{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:13:40Z","timestamp":1792419220736,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.seminhematol.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T13:55:43Z","timestamp":1463061343000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance"],"prefix":"10.1053","volume":"53","author":[{"given":"Andrea K.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2016.05.008_bib1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/cncr.24178","article-title":"Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials","volume":"115","author":"Favier","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib2","series-title":"Hodgkin lymphoma: a comprenhensive overview hematology malignancies","first-page":"411","article-title":"Cardiovascular and pulmonary late effects","author":"Aleman","year":"2015"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib4","series-title":"Hodgkin lymphoma: a comprenhensive overview hematology malignancies","first-page":"375","article-title":"Second malignancy risk after treatment of Hodgkin lymphoma","author":"Hodgson","year":"2015"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib5","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib6","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib7","series-title":"New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000","article-title":"New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma","author":"Dores","year":"2006"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib8","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib11","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib12","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: report from the Late Effects Study Group","volume":"21","author":"Bhatia","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib13","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.semradonc.2009.09.002","article-title":"Secondary malignancies across the age spectrum","volume":"20","author":"Ng","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib15","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib18","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","article-title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma","volume":"25","author":"Dores","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib21","first-page":"695","article-title":"Lung cancer after Hodgkin lymphoma: the roles of chemotherapy, radiotherapy and tobacco use","volume":"163","author":"Travis","year":"2005","journal-title":"Radiat Res"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","article-title":"Lung cancer after treatment for Hodgkin\u2019s disease: focus on radiation effects","volume":"159","author":"Gilbert","year":"2003","journal-title":"Radiat Res"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib23","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","article-title":"Lung cancer after Hodgkin\u2019s disease: a nested case-control study of the relation to treatment","volume":"19","author":"Swerdlow","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","article-title":"Cardiovascular disease after cancer therapy","volume":"12","author":"Aleman","year":"2014","journal-title":"EJC Suppl"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib25","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1146\/annurev-med-070213-054849","article-title":"Cardiovascular disease in adult survivors of childhood cancer","volume":"66","author":"Lipshultz","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib28","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1667\/RR1862.1","article-title":"Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients","volume":"174","author":"Stewart","year":"2010","journal-title":"Radiat Res"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2353\/ajpath.2006.050409","article-title":"Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-\/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage","volume":"168","author":"Stewart","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/annonc\/mdu130","article-title":"Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance","volume":"25","author":"Daniels","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2014.01.021","article-title":"Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","article-title":"Screening for coronary artery disease after mediastinal irradiation for Hodgkin\u2019s disease","volume":"25","author":"Heidenreich","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2009.25.2627","article-title":"Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin\u2019s lymphoma","volume":"28","author":"Kupeli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1053-4296(03)00026-2","article-title":"Radiation-associated cardiovascular disease: manifestations and management","volume":"13","author":"Adams","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib35","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib37","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib39","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.008_bib40","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib41","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib42","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib43","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2015.64.6588","article-title":"Minimizing cardiac risks with contemporary radiation therapy for Hodgkin lymphoma","volume":"34","author":"Maraldo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","article-title":"Lung function impairment in long-term survivors of Hodgkin\u2019s disease","volume":"6","author":"Lund","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00277-011-1255-7","article-title":"Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors","volume":"91","author":"Avivi","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/pbc.24969","article-title":"Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation","volume":"61","author":"Venkatramani","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199108293250902","article-title":"Thyroid diseases after treatment of Hodgkin\u2019s disease","volume":"325","author":"Hancock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.1-1-62","article-title":"Thyroid abnormalities after therapy for hodgkin\u2019s disease in childhood","volume":"1","author":"Bhatia","year":"1996","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib51","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ijrobp.2010.09.054","article-title":"Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin\u2019s lymphoma","volume":"82","author":"Cella","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jncimonographs\/lgi003","article-title":"Spermatogenesis after cancer treatment: damage and recovery","author":"Howell","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1259\/0007-1285-53-628-271","article-title":"The influence of radiation on fertility in man","volume":"53","author":"Ash","year":"1980","journal-title":"Br J Radiol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jncimonographs\/lgi022","article-title":"Impact of cancer treatment on uterine function","author":"Critchley","year":"2005","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.802","article-title":"Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","volume":"25","author":"Hodgson","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib56","first-page":"1032","article-title":"Treatment of early-stage Hodgkin\u2019s disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity","volume":"85","author":"Brusamolino","year":"2000","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib58","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin\u2019s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin\u2019s Lymphoma Study Group","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib60","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.2013.54.4379","article-title":"Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma","volume":"32","author":"van Nimwegen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib61","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijrobp.2010.11.064","article-title":"Progressive muscle atrophy and weakness after treatment by mantle field radiotherapy in Hodgkin lymphoma survivors","volume":"82","author":"van Leeuwen-Segarceanu","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.1999.17.1.253","article-title":"Hodgkin\u2019s disease survivors more fatigued than the general population","volume":"17","author":"Loge","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib63","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0959-8049(03)00545-8","article-title":"Fatigue in long-term survivors of Hodgkin\u2019s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)","volume":"39","author":"Ruffer","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib64","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/annonc\/mdi407","article-title":"A comparison between long-term survivors of Hodgkin\u2019s disease and their siblings on fatigue level and factors predicting for increased fatigue","volume":"16","author":"Ng","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib65","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1200\/JCO.2005.09.936","article-title":"Fatigue in long-term Hodgkin\u2019s disease survivors: a follow-up study","volume":"23","author":"Hjermstad","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib66","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-013-1793-2","article-title":"Persisting fatigue in Hodgkin lymphoma survivors: a systematic review","volume":"92","author":"Daniels","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib67","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1200\/JCO.2001.19.13.3226","article-title":"Late medical complications and fatigue in Hodgkin\u2019s disease survivors","volume":"19","author":"Knobel","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib68","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/bjc.2013.779","article-title":"Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity","volume":"110","author":"Daniels","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(02)00483-5","article-title":"Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors\u2014results from a pilot study","volume":"39","author":"Oldervoll","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2016.05.008_bib70","unstructured":"NCCN clinical practice guidelines in oncology. Hodgkin lymphoma. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf Version 2, 2015."},{"key":"10.1053\/j.seminhematol.2016.05.008_bib71","unstructured":"Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 4.0. http:\/\/www.survivorshipguidelines.org\/pdf\/ltfuguidelines.pdf, 2013."}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:24:57Z","timestamp":1758522297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196316300452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0037196316300452"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}